Gut and oral microbiome profiles in patients with obesity and ischemic heart disease
Frontiers in Cellular and Infection Microbiology · 2025
DOI: 10.3389/fcimb.2025.1695279 ↗Kurz gefasst
Fachartikel in der Zeitschrift Frontiers in Cellular and Infection Microbiology, 2025. Verfasst von Antonina Starodubova und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiovascular Pathology and Diet Therapy, Federal Research Center of Nutrition, Biotechnology and Food Safety, Moscow, Russia. Hauptthemen laut MEDLINE: Obesity, Myocardial Ischemia, Gastrointestinal Microbiome, Mouth. Die Arbeit nennt 68 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Russian Science Foundation.
Abstract (Originalsprache)
Background
Ischemic heart disease (IHD) and obesity are major contributors to global mortality. Both conditions are linked to systemic inflammation, dyslipidemia, and microbiota alterations. This study examines the relationship between the composition of the gut and oral microbiota, obesity, and IHD to gain insight into the interconnections between these factors.
Methods
The study included 182 participants divided into four groups based on obesity and IHD status. Anthropometric and biochemical analyses were performed. Oral and gut microbiomes were analyzed using 16S rRNA sequencing.
Results
Obesity and IHD were associated with distinct microbiota compositions. Obesity-IHD subjects showed elevated levels of gut Streptococcus, Intestinibacter , alongside reduced Citrobacter, Ruthenibacterium, Parabacteroides, and Flavonifractor . The oral microbiota exhibited decreased Alloprevotella, Capnocytophaga, Prevotellamassilia, and Campylobacter in Obesity-IHD. Correlation analysis highlighted associations between microbial taxa (e.g., Blautia , Oscillibacter ) and clinical parameters like BMI, blood pressure, and cholesterol.
Conclusions
This study demonstrates that obesity and IHD are linked to unique microbiota alterations. Microbial dysbiosis may contribute to the pathogenesis of these conditions and should be considered as a therapeutic target in the development of personalized treatment strategies of the obesity and associated cardiovascular complications.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Cardiovascular Pathology and Diet Therapy, Federal Research Center of Nutrition, Biotechnology and Food Safety, Moscow, Russia.
- Institute of Clinical Medicine, Pirogov Russian National Research Medical University, Moscow, Russia.
- Petrovsky National Research Center of Surgery, Moscow, Russia.
- Nobias Technologies, Moscow, Russia.
- Institute of General Pathology and Pathophysiology, Moscow, Russia.
Förderung
- Russian Science Foundation
Zitieren
APA
Starodubova, A., Leonov, G., Shaposhnikova, N., Varaeva, Y., Livantsova, E., Fotin, D., Kirichenko, T., Bagheri Ekta, M., Markina, Y., Koshechkin, S., Orekhov, A., & Nikityuk, D. (2025). Gut and oral microbiome profiles in patients with obesity and ischemic heart disease. Frontiers in Cellular and Infection Microbiology. https://doi.org/10.3389/fcimb.2025.1695279
Vancouver
Starodubova A, Leonov G, Shaposhnikova N, Varaeva Y, Livantsova E, Fotin D, et al. Gut and oral microbiome profiles in patients with obesity and ischemic heart disease. Frontiers in Cellular and Infection Microbiology. 2025. doi:10.3389/fcimb.2025.1695279
BibTeX
@article{Starodubova2025,
author = {Starodubova, Antonina and Leonov, Georgy and Shaposhnikova, Nataliya and Varaeva, Yurgita and Livantsova, Elena and Fotin, Denis and Kirichenko, Tatiana and Bagheri Ekta, Mariam and Markina, Yuliya and Koshechkin, Stanislav and Orekhov, Alexander and Nikityuk, Dmitry},
title = {Gut and oral microbiome profiles in patients with obesity and ischemic heart disease},
journal = {Frontiers in Cellular and Infection Microbiology},
year = {2025},
doi = {10.3389/fcimb.2025.1695279}
}
EUVIMED